Thirty-Day Readmissions After Hospitalization for Psoriatic Arthritis
Fidelis Uwumiro, Solomon O Anighoro, Adetayo Ajiboye, Chukwunonso C Ndulue, God-dowell O Odukudu, Emeka S Obi, Stanley C Ndugba, Claire A Ewelugo, Evaristus Asobara, Okonkwo Ogochukwu

TL;DR
This study finds that nearly one-third of hospitalizations for psoriatic arthritis lead to readmission within 30 days, with factors like age and comorbidities playing a role.
Contribution
The study identifies specific predictors and common causes of 30-day readmissions for psoriatic arthritis patients in the U.S.
Findings
29% of PsA hospitalizations resulted in 30-day readmissions, primarily due to acute kidney failure, major depression, and heart failure.
Readmitted patients were younger, more often uninsured, and had higher hospital costs and longer stays than those with index admissions.
Age under 40, home healthcare discharge, and secondary diagnoses of inflammatory bowel disease or deep venous thrombosis increased readmission risk.
Abstract
Background Psoriatic arthritis (PsA) is correlated with higher rates of major adverse cardiovascular events and autoimmune disorders than the general population, leading to more frequent hospitalizations. This study assessed the rates and characteristics of index and 30-day readmissions among adults hospitalized for PsA and evaluated the indications and predictors of 30-day readmissions across the United States. Methodology We analyzed the 2020 Nationwide Readmissions Database for adult PsA hospitalizations using the International Classification of Diseases, Tenth Revision, Clinical Modification codes. To compare baseline characteristics between index admissions and readmissions, we used chi-square tests. We used ranking commands to identify the most common indications for readmissions and multivariable Cox regression analysis to identify the predictors of readmissions. The primary…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical Practices and Patient Outcomes · Chronic Disease Management Strategies · Childhood Cancer Survivors' Quality of Life
